-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network News, August 5 Recently, Sichuan Meidakang Pharmaceutical's 4 generic listing applications for Memantine Hydrochloride Tablets have entered the approval status
.
According to data from Minai.
com, Memantine is the TOP1 type of anti-dementia drug in China's public medical institutions, and its sales at physical pharmacies in cities in China have grown at a double-digit rate for three consecutive years
.
Memantine hydrochloride tablets are the third batch of nationally sourced catalog varieties and will be implemented in the fourth quarter of 2020
.
.
According to data from Minai.
com, Memantine is the TOP1 type of anti-dementia drug in China's public medical institutions, and its sales at physical pharmacies in cities in China have grown at a double-digit rate for three consecutive years
.
Memantine hydrochloride tablets are the third batch of nationally sourced catalog varieties and will be implemented in the fourth quarter of 2020
.
Figure 1: Product information under review
Source: NMPA official website
Memantine is an excitatory amino acid receptor antagonist used to treat moderate to severe Alzheimer's dementia
.
At present, the memantine-related products on the domestic market include memantine hydrochloride oral solution, memantine hydrochloride tablets and memantine hydrochloride sustained-release capsules
.
.
At present, the memantine-related products on the domestic market include memantine hydrochloride oral solution, memantine hydrochloride tablets and memantine hydrochloride sustained-release capsules
.
According to data from Minai.
com, Memantine defeated Donepezil and became the TOP1 anti-dementia drug in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020
.
At present, the leading company in this category is Lingbei , with a market share of up to 80%, and the main product involved is memantine hydrochloride tablets
.
With the implementation of the third batch of national procurement, the market shares of the four winning bidders of Baiyunshan, Hunan Dongting Pharmaceutical, Anhui Huachen Pharmaceutical, and CSPC Ouyi Pharmaceutical are expected to increase, and the failure of original research pharmaceutical companies is a foregone conclusion
.
com, Memantine defeated Donepezil and became the TOP1 anti-dementia drug in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020
.
At present, the leading company in this category is Lingbei , with a market share of up to 80%, and the main product involved is memantine hydrochloride tablets
.
With the implementation of the third batch of national procurement, the market shares of the four winning bidders of Baiyunshan, Hunan Dongting Pharmaceutical, Anhui Huachen Pharmaceutical, and CSPC Ouyi Pharmaceutical are expected to increase, and the failure of original research pharmaceutical companies is a foregone conclusion
.
Figure 2: The sales of Memantine in the retail market (unit: ten thousand yuan)
Source: Meinenet.
com China's urban retail pharmacy terminal layout
com China's urban retail pharmacy terminal layout
In the physical pharmacies of Chinese cities , the sales of Memantine are achieving rapid growth.
The growth rate of 2018-2019 has remained above 10%, and the growth rate in 2020 is as high as 20%.
If this growth trend is maintained, it is expected to exceed 100 million in 2021.
.
Lundbeck is also the leader in the retail market, but United Laboratories has become the strongest competitor, with a market share of only 0.
48% in 2015 and 13.
09% in 2020
.
It is also worth paying attention to how Sichuan Meidakang Pharmaceutical will deploy its market after entering the market
.
The growth rate of 2018-2019 has remained above 10%, and the growth rate in 2020 is as high as 20%.
If this growth trend is maintained, it is expected to exceed 100 million in 2021.
.
Lundbeck is also the leader in the retail market, but United Laboratories has become the strongest competitor, with a market share of only 0.
48% in 2015 and 13.
09% in 2020
.
It is also worth paying attention to how Sichuan Meidakang Pharmaceutical will deploy its market after entering the market
.
Data source: CDE official website, Minet database
Pharmaceutical Network News, August 5 Recently, Sichuan Meidakang Pharmaceutical's 4 generic listing applications for Memantine Hydrochloride Tablets have entered the approval status
.
According to data from Minai.
com, Memantine is the TOP1 type of anti-dementia drug in China's public medical institutions, and its sales at physical pharmacies in cities in China have grown at a double-digit rate for three consecutive years
.
Memantine hydrochloride tablets are the third batch of nationally sourced catalog varieties and will be implemented in the fourth quarter of 2020
.
.
According to data from Minai.
com, Memantine is the TOP1 type of anti-dementia drug in China's public medical institutions, and its sales at physical pharmacies in cities in China have grown at a double-digit rate for three consecutive years
.
Memantine hydrochloride tablets are the third batch of nationally sourced catalog varieties and will be implemented in the fourth quarter of 2020
.
Figure 1: Product information under review
Source: NMPA official website
Memantine is an excitatory amino acid receptor antagonist used to treat moderate to severe Alzheimer's dementia
.
At present, the memantine-related products on the domestic market include memantine hydrochloride oral solution, memantine hydrochloride tablets and memantine hydrochloride sustained-release capsules
.
.
At present, the memantine-related products on the domestic market include memantine hydrochloride oral solution, memantine hydrochloride tablets and memantine hydrochloride sustained-release capsules
.
According to data from Minai.
com, Memantine defeated Donepezil and became the TOP1 anti-dementia drug in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020
.
At present, the leading company in this category is Lingbei , with a market share of up to 80%, and the main product involved is memantine hydrochloride tablets
.
With the implementation of the third batch of national procurement, the market shares of the four winning bidders of Baiyunshan, Hunan Dongting Pharmaceutical, Anhui Huachen Pharmaceutical, and CSPC Ouyi Pharmaceutical are expected to increase, and the failure of original research pharmaceutical companies is a foregone conclusion
.
com, Memantine defeated Donepezil and became the TOP1 anti-dementia drug in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020
.
At present, the leading company in this category is Lingbei , with a market share of up to 80%, and the main product involved is memantine hydrochloride tablets
.
With the implementation of the third batch of national procurement, the market shares of the four winning bidders of Baiyunshan, Hunan Dongting Pharmaceutical, Anhui Huachen Pharmaceutical, and CSPC Ouyi Pharmaceutical are expected to increase, and the failure of original research pharmaceutical companies is a foregone conclusion
.
Figure 2: The sales of Memantine in the retail market (unit: ten thousand yuan)
Source: Meinenet.
com China's urban retail pharmacy terminal layout
com China's urban retail pharmacy terminal layout
In the physical pharmacies of Chinese cities , the sales of Memantine are achieving rapid growth.
The growth rate of 2018-2019 has remained above 10%, and the growth rate in 2020 is as high as 20%.
If this growth trend is maintained, it is expected to exceed 100 million in 2021.
.
Lundbeck is also the leader in the retail market, but United Laboratories has become the strongest competitor, with a market share of only 0.
48% in 2015 and 13.
09% in 2020
.
It is also worth paying attention to how Sichuan Meidakang Pharmaceutical will deploy its market after entering the market
.
The growth rate of 2018-2019 has remained above 10%, and the growth rate in 2020 is as high as 20%.
If this growth trend is maintained, it is expected to exceed 100 million in 2021.
.
Lundbeck is also the leader in the retail market, but United Laboratories has become the strongest competitor, with a market share of only 0.
48% in 2015 and 13.
09% in 2020
.
It is also worth paying attention to how Sichuan Meidakang Pharmaceutical will deploy its market after entering the market
.
Data source: CDE official website, Minet database
Pharmaceutical Network News, August 5 Recently, Sichuan Meidakang Pharmaceutical's 4 generic listing applications for Memantine Hydrochloride Tablets have entered the approval status
.
According to data from Minai.
com, Memantine is the TOP1 type of anti-dementia drug in China's public medical institutions, and its sales at physical pharmacies in cities in China have grown at a double-digit rate for three consecutive years
.
Memantine hydrochloride tablets are the third batch of nationally sourced catalog varieties and will be implemented in the fourth quarter of 2020
.
.
According to data from Minai.
com, Memantine is the TOP1 type of anti-dementia drug in China's public medical institutions, and its sales at physical pharmacies in cities in China have grown at a double-digit rate for three consecutive years
.
Memantine hydrochloride tablets are the third batch of nationally sourced catalog varieties and will be implemented in the fourth quarter of 2020
.
Figure 1: Product information under review
Source: NMPA official website
Memantine is an excitatory amino acid receptor antagonist used to treat moderate to severe Alzheimer's dementia
.
At present, the memantine-related products on the domestic market include memantine hydrochloride oral solution, memantine hydrochloride tablets and memantine hydrochloride sustained-release capsules
.
.
At present, the memantine-related products on the domestic market include memantine hydrochloride oral solution, memantine hydrochloride tablets and memantine hydrochloride sustained-release capsules
.
According to data from Minai.
com, Memantine defeated Donepezil and became the TOP1 anti-dementia drug in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020
.
At present, the leading company in this category is Lingbei , with a market share of up to 80%, and the main product involved is memantine hydrochloride tablets
.
With the implementation of the third batch of national procurement, the market shares of the four winning bidders of Baiyunshan, Hunan Dongting Pharmaceutical, Anhui Huachen Pharmaceutical, and CSPC Ouyi Pharmaceutical are expected to increase, and the failure of original research pharmaceutical companies is a foregone conclusion
.
Hospital Hospital Hospital Enterprise Enterprise Enterprisecom, Memantine defeated Donepezil and became the TOP1 anti-dementia drug in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020
.
At present, the leading company in this category is Lingbei , with a market share of up to 80%, and the main product involved is memantine hydrochloride tablets
.
With the implementation of the third batch of national procurement, the market shares of the four winning bidders of Baiyunshan, Hunan Dongting Pharmaceutical, Anhui Huachen Pharmaceutical, and CSPC Ouyi Pharmaceutical are expected to increase, and the failure of original research pharmaceutical companies is a foregone conclusion
.
Figure 2: The sales of Memantine in the retail market (unit: ten thousand yuan)
Source: Meinenet.
com China's urban retail pharmacy terminal layout
com China's urban retail pharmacy terminal layout
In the physical pharmacies of Chinese cities , the sales of Memantine are achieving rapid growth.
The growth rate of 2018-2019 has remained above 10%, and the growth rate in 2020 is as high as 20%.
If this growth trend is maintained, it is expected to exceed 100 million in 2021.
.
Lundbeck is also the leader in the retail market, but United Laboratories has become the strongest competitor, with a market share of only 0.
48% in 2015 and 13.
09% in 2020
.
It is also worth paying attention to how Sichuan Meidakang Pharmaceutical will deploy its market after entering the market
.
Pharmacy pharmacy pharmacyThe growth rate of 2018-2019 has remained above 10%, and the growth rate in 2020 is as high as 20%.
If this growth trend is maintained, it is expected to exceed 100 million in 2021.
.
Lundbeck is also the leader in the retail market, but United Laboratories has become the strongest competitor, with a market share of only 0.
48% in 2015 and 13.
09% in 2020
.
It is also worth paying attention to how Sichuan Meidakang Pharmaceutical will deploy its market after entering the market
.
Data source: CDE official website, Minet database
